Intrommune, Author at Intrommune Therapeutics

Intrommune Therapeutics Announces Independent Editorial Highlighting Breakthrough Safety Data for Novel Toothpaste Peanut Allergy Treatment

The editorial, authored by leading allergists, Dr. Aikaterini Anagnostou and Dr. David Stukus, discusses the key findings of the OMEGA (Oral Mucosal Escalation Goal Assessment) trial, a randomized, double blind placebo-controlled Phase 1 study, evaluating the safety of its investigational treatment, OMIT with INT301 (peanut protein) in peanut allergic adults.

Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology

Press Releases / By Intrommune

Groundbreaking Study Demonstrates Safety and Tolerability of Oral Mucosal Immunotherapy (OMIT) for Peanut Allergy Using Toothpaste.

Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events

Press Releases / By Intrommune

Last week, the Intrommune team presented in support of its Oral Mucosal Immunotherapy (OMIT) at Citizens JMP Life Science Conference and the BioNJ BioPartnering Conference, and CEO Michael Nelson will represent Intrommune as a panelist at this year’s Annual Food Allergy Fund Summit.

Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya

Press Releases / By Intrommune

Intrommune today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.

Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment

Press Releases / By Intrommune

New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy.

Intrommune Therapeutics to Present a New Form of Allergy Treatment at the 2024 AAAAI Annual Meeting

Press Releases / By Intrommune

New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy.

Inimmune Corporation and Intrommune Therapeutics Announce a Collaboration to Advance a Revolutionary Rapid, Long-acting Oral Mucosal Allergy Immunotherapy for the Treatment of Peanut Allergy

Press Releases / By Intrommune

The combination of these two approaches is expected to result in the rapid and long-term relief of allergic symptoms resulting from peanut exposure and would be a game changer for patients suffering with this potentially life-threatening allergy.

Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy

Press Releases / By Intrommune

Study met all primary and secondary safety endpoints, demonstrating INT301 was well-tolerated. A small subset analysis provided indications of efficacy. Full data set to be reported next year, followed by initiation of the Phase 2 clinical trial in a pediatric population.

Teach Them to Fish – Inspiring Self Confidence in Kids with Food Allergies

Blog / By Intrommune

It’s natural (and necessary!) to relentlessly protect our little ones, especially while they’re still learning how to navigate life with a food allergy. But when it comes time for them to take off on their own, how can you make sure they have the skills to succeed?

Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy

Press Releases / By Intrommune